• metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
• mNSCLC - L1 - all population 5
• mNSCLC - L1 - EGFR mutant
• mNSCLC - L1 - PDL1 negative 1
• mNSCLC - L1 - PDL1 positive 14
• mNSCLC - L1 - TMB>10Mb 1
• non squamous cell - mNSCLC - L1
• non squamous - mNSCLC - L1 - all population 3
• non squamous - mNSCLC - L1 - PDL1 positive
• non squamous - mNSCLC - L1 - Wild Type (WT) 6
• squamous cell - mNSCLC - L1
• squamous - mNSCLC - L1 - all population 4
• squamous - mNSCLC - L1 - PDL1 positive
• squamous - mNSCLC - L1 - Wild Type (WT)

 

• gene alteration target therapy
• EGFR gene alteration
• osimertinib
• HER inhibitor
• EGFR inhibitor
• erlotinib based treatment
• erlotinib alone
• erlotinib plus cisplatin and gemcitabine
• erlotinib plus SoC
• gefitinib based treatment
• gefitinib alone
• gefitinib plus BSC
• gefitinib plus SoC
• SoC followed by gefitinib
• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab alone
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• cemiplimab
• durvalumab based treatment
• durvalumab alone
• nivolumab based treatment
• nivolumab alone
• sintilimab based treatment
• sintillimab plus SoC
• sugemalimab based treatment
• sugemalimab plus SoC
• Immune checkpoint association
• durvalumab plus tremelimumab
• nivolumab plus ipilimumab
• nivolumab plus ipilimumab plus SoC
• VEGF(R) inhibitor
• sorafenib
• sorafenib and erlotinib

no study with result for this clinical condition